TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1836100

Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor)
Number of subjects: 2220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2220
Study: 6137426

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 40
Study: 31045798

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (cholecalciferol) at 14,000 IU per week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (cholecalciferol) at 28,000 IU per week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29119301

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cardiovascular training (ergometer)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 64
Study: 26919177

Group type: EXPERIMENTAL
Intervention: Cold exposure (16°C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Warm condition (23°C)
Number of subjects: 24
Study: 24127243

Group type: EXPERIMENTAL
Intervention: Knee confidence
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pain during walking
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Self-reported knee instability
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quadriceps strength
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dynamic varus-valgus joint motion during walking
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multivariable model of pain, instability, strength, and motion
Number of subjects: 100
Study: 22194501

Group type: EXPERIMENTAL
Intervention: Positron emission mammography (PEM)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: PEM
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: PEM (blinded retrospective review)
Number of subjects: 367
Study: 21035633

Group type: EXPERIMENTAL
Intervention: Escitalopram (20mg)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Paroxetine (40mg)
Number of subjects: 459
Study: 17392539

Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Regular human insulin (HI)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp) and Regular human insulin (HI)
Number of subjects: 322
Study: 16392300

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 50

Group type: COMPARATOR
Intervention: ACE inhibitors (ACEIs)
Number of subjects: 50
Study: 12062374

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA (1.65 g per day)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 10214573

Group type: EXPERIMENTAL
Intervention: ADCON-L (Adhesion Control in a Barrier Gel)
Number of subjects: 20
Study: 7890391

Group type: EXPERIMENTAL
Intervention: Bivalent formulation (vibrio cholerae CVD 103‐HgR and Salmonella typhi Ty21a)
Number of subjects: 185

Group type: COMPARATOR
Intervention: CVD 103‐HgR followed by two doses of killed Escherichia coli K‐12 placebo
Number of subjects: 185
Study: 1982881

Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Quazepam (15 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 140029

Group type: EXPERIMENTAL
Intervention: Combination of a diuretic and rauwolfia serpentina
Number of subjects: 389

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 389
Study: 31743188

Group type: EXPERIMENTAL
Intervention: Optiscope
Number of subjects: 21

Group type: COMPARATOR
Intervention: McGrath videolaryngoscope
Number of subjects: 21
Study: 28595744

Group type: EXPERIMENTAL
Intervention: FES+Walk
Number of subjects: 27

Group type: COMPARATOR
Intervention: WALK
Number of subjects: 27
Study: 23348842

Group type: EXPERIMENTAL
Intervention: Kava (120 mg of kavalactones per day, titrated to 240 mg if non-response)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 21753154

Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg QD (n = 23)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg TIW (n = 22)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg QW (n = 22)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg QD (loading dose for 11 days)
Number of subjects: 67
Study: 19112166

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/d
Number of subjects: 803

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study: 17003947

Group type: EXPERIMENTAL
Intervention: Bibrocathol 5% ointment
Number of subjects: 197

Group type: COMPARATOR
Intervention: Ointment vehicle (control)
Number of subjects: 197
Study: 15267037

Group type: EXPERIMENTAL
Intervention: Oral artesunate (200 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rectal artesunate (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both routes of administration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rectal artesunate
Number of subjects: 12
Study: 10881461

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 322
Study: 9453088

Group type: EXPERIMENTAL
Intervention: TSB trans-tibial prosthesis with ICEROSS system
Number of subjects: 0

Group type: COMPARATOR
Intervention: PTB trans-tibial prosthesis
Number of subjects: 0
Study: 7711417

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 30
Study: 3273207

Group type: EXPERIMENTAL
Intervention: Hollow-fibre membrane oxygenator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard bubble oxygenator
Number of subjects: 0
Study: 29165029

Group type: EXPERIMENTAL
Intervention: Tracker-based activity intervention (Jawbone Up24 tracker worn for ≥5 days and completed weekly calls)
Number of subjects: 35
Study: 29266189

Group type: EXPERIMENTAL
Intervention: Clofarabine (CLOF) 30 mg/m2/d × 5, along with cyclophosphamide (CPM), etoposide (ETOP), vincristine (VCR), and pegaspargase (experimental arm 2)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPM), etoposide (ETOP), vincristine (VCR), and pegaspargase (experimental arm 1)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control arm: Cyclophosphamide (CPM), cytarabine, mercaptopurine, vincristine (VCR), and pegaspargase
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Clofarabine (CLOF) 20 mg/m2/d × 5 (after dose reduction due to toxicity), along with cyclophosphamide (CPM) and etoposide (ETOP)
Number of subjects: 105
Study: 26438645

Group type: EXPERIMENTAL
Intervention: THS 2.1
Number of subjects: 28

Group type: COMPARATOR
Intervention: CCs
Number of subjects: 28
Study: 24530680

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 2292

Group type: COMPARATOR
Intervention: XIENCE V everolimus-eluting stent (EES)
Number of subjects: 2292
Study: 23268820

Group type: EXPERIMENTAL
Intervention: Single-bundle ACL reconstruction
Number of subjects: 34

Group type: COMPARATOR
Intervention: Dual-bundle ACL reconstruction
Number of subjects: 34
Study: 18583022

Group type: EXPERIMENTAL
Intervention: tolterodine ER+tamsulosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tamsulosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tolterodine ER
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 17201517

Group type: EXPERIMENTAL
Intervention: Abstinence-based teen pregnancy prevention program
Number of subjects: 1136
Study: 15111756

Group type: EXPERIMENTAL
Intervention: Surgical treatment (radical type II or III hysterectomy and lymphonodectomy) for early stage I and IIA cervical cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiation therapy or concomitant chemoradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiation (external beam radiotherapy with chemotherapy and brachytherapy)
Number of subjects: 0
Study: 10743326

Group type: EXPERIMENTAL
Intervention: Personalized reminder leaflet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 0
Study: 9197872

Group type: EXPERIMENTAL
Intervention: Combined antioxidant treatment with vitamin E (800 IU/day), vitamin C (1000 mg/day), and allopurinol (200 mg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combined antioxidant treatment
Number of subjects: 56
Study: 1546498

Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with pyloroplasty (SPV + P)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective proximal vagotomy without pyloroplasty (SPV - P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy (SPV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with and without pyloroplasty (SPV + P and SPV - P)
Number of subjects: 0
Study: 2988589

Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 mg/day
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg/day
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg/day
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg/day
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Enalapril 40 mg/day
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 3106233

Group type: EXPERIMENTAL
Intervention: Pseudomonas hyperimmune globulin (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (n = 15)
Number of subjects: 30
Study: 29955866

Group type: EXPERIMENTAL
Intervention: Intervention (nurse care manager support, electronic registry, academic detailing, and electronic tools)
Number of subjects: 985

Group type: COMPARATOR
Intervention: Control (electronic tools only)
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 985

Group type: COMPARATOR
Intervention: Control
Number of subjects: 985
Study: 27890303

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate 6g daily as adjunctive therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 26595967

Group type: EXPERIMENTAL
Intervention: Halotherapy (HT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Magnetic therapy (MT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of HT and MT
Number of subjects: 120
Study: 24205135

Group type: EXPERIMENTAL
Intervention: Generic alendronate
Number of subjects: 37

Group type: COMPARATOR
Intervention: Branded alendronate
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both generic and branded alendronate
Number of subjects: 37
Study: 20508534

Group type: EXPERIMENTAL
Intervention: Roman chair exercise with hips flexed at 40°
Number of subjects: 34
Study: 18438806

Group type: EXPERIMENTAL
Intervention: Hospitalist-Care Coordinator (HCC) team
Number of subjects: 693

Group type: COMPARATOR
Intervention: Control group (hospitalists working independently)
Number of subjects: 693
Study: 16929704

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12769148

Group type: EXPERIMENTAL
Intervention: Menicon Z rigid gas‐permeable (RGP) contact lenses
Number of subjects: 60

Group type: COMPARATOR
Intervention: ACUVUE hydrogel lenses
Number of subjects: 60
Study: 10694106

Group type: EXPERIMENTAL
Intervention: Stretch group (20-s static stretch for each of six major leg muscle groups during warm-up)
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: Both groups (preexercise stretching effect)
Number of subjects: 1538
Study: 9062091

Group type: EXPERIMENTAL
Intervention: Anaritide (0.2 microgram per kilogram of body weight per minute)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study: 8446441

Group type: EXPERIMENTAL
Intervention: Oral fenfluramine (60 mg)/morphine infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral fenfluramine (60 mg)/saline infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral placebo/morphine infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral placebo/saline infusion
Number of subjects: 10
Study: 3947405

Group type: EXPERIMENTAL
Intervention: Alternative radiologic techniques for assessing joint destruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommended techniques for radiologic assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of multiple readers with varying experience levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reading films in pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluating 34 joints versus 18 joints
Number of subjects: 0
Study: 28885296

Group type: EXPERIMENTAL
Intervention: Mechanically Assisted Instrument (MAI) applied to C5 of the spine, maximum setting, duration not specified.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (MAI turned off), duration not specified.
Number of subjects: 125
Study: 26226096

Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery (LARS)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Esomeprazole (20 or 40 mg/d)
Number of subjects: 267
Study: 23562749

Group type: COMPARATOR
Intervention: Heavy training (2 weeks)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Light training (2 weeks)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Heart rate recovery
Number of subjects: 17
Study: 22627597

Group type: EXPERIMENTAL
Intervention: 80-kVp protocol with a 40% reduction in contrast agent dose and hybrid iterative reconstruction algorithm
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Hybrid iterative reconstruction
Number of subjects: 74

Group type: COMPARATOR
Intervention: 80-kVp with iterative reconstruction
Number of subjects: 74
Study: 20022087

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 40 mg hyaluronic acid (HA) weekly for the first month, then monthly for 2 months.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intravesical heparin treatment.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Hydrodistention alone (control group).
Number of subjects: 47
Study: 17764888

Group type: EXPERIMENTAL
Intervention: SLN biopsy associated with ALND (ALND arm)
Number of subjects: 697

Group type: COMPARATOR
Intervention: SLN biopsy followed by ALND only if SLN was metastatic (SLN arm)
Number of subjects: 697
Study: 16859191

Group type: COMPARATOR
Intervention: Pyridoxine treatment
Number of subjects: 0
Study: 12492665

Group type: EXPERIMENTAL
Intervention: Nitrous oxide in 30% oxygen
Number of subjects: 18

Group type: COMPARATOR
Intervention: Air/nitrous oxide/air
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/air/nitrous oxide
Number of subjects: 18
Study: 10801243

Group type: EXPERIMENTAL
Intervention: Indinavir sulfate 800 mg every 8 hours with placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg every 12 hours with placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indinavir sulfate with clarithromycin
Number of subjects: 12
Study: 8632119

Group type: EXPERIMENTAL
Intervention: Whipple procedure
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (post-cholecystectomy)
Number of subjects: 24
Study: 1484193

Group type: EXPERIMENTAL
Intervention: High-viscosity suppository formulation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low-viscosity suppository formulation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral controlled-release morphine sulfate tablets
Number of subjects: 14
Study: 3833089

Group type: EXPERIMENTAL
Intervention: Randt Memory Test (RMT) - five different parallel forms
Number of subjects: 20
Study: 30829658

Group type: EXPERIMENTAL
Intervention: Nociception level-guided analgesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study: 28459397

Group type: EXPERIMENTAL
Intervention: Closed tracheal suction group
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Splash-proof suction group
Number of subjects: 318

Group type: COMPARATOR
Intervention: Open tracheal suction group
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 318
Study: 26372883

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 496
Study: 25675612

Group type: EXPERIMENTAL
Intervention: Soft toothbrush
Number of subjects: 15

Group type: COMPARATOR
Intervention: Brushless tooth cleaner
Number of subjects: 15
Study: 22664645

Group type: EXPERIMENTAL
Intervention: FACE intervention
Number of subjects: 130

Group type: COMPARATOR
Intervention: Healthy Living Control
Number of subjects: 130
Study: 19064965

Group type: EXPERIMENTAL
Intervention: Chemotherapy (at least two cycles)
Number of subjects: 117
Study: 17312085

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate supplementation plus resistance training (CRE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (lactose monohydrate) plus resistance training (PLA)
Number of subjects: 20
Study: 15458276

Group type: EXPERIMENTAL
Intervention: Fish oil group (n-3 fatty acids supplement)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no special diet or intervention)
Number of subjects: 60
Study: 11340105

Group type: EXPERIMENTAL
Intervention: Oral exposure to butter
Number of subjects: 17

Group type: COMPARATOR
Intervention: Fat replacers
Number of subjects: 17

Group type: COMPARATOR
Intervention: No oral stimulation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Potatoes
Number of subjects: 17

Group type: COMPARATOR
Intervention: Potatoes containing butter
Number of subjects: 17
Study: 9683309

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy (0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone acetate daily)
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study: 7831623

Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amiloride 7.5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3262097

Group type: EXPERIMENTAL
Intervention: 1 g acetazolamide (ACZ)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (pre-ACZ study)
Number of subjects: 15
Study: 31340842

Group type: EXPERIMENTAL
Intervention: 4CMenB booster dose
Number of subjects: 113

Group type: COMPARATOR
Intervention: 4CMenB two doses (0 and 28 days or 0 and 365 days)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: 4CMenB doses
Number of subjects: 113
Study: 27316706

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine 500 mg/day for 6 months
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 27999775

Group type: EXPERIMENTAL
Intervention: High tidal volume (HVT) 10 mL/kg of predicted body weight (PBW)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low tidal volume (LVT) 6 mL/kg PBW
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low tidal volume combined with moderate hypercapnia (LVT + HC) 6 mL/kg PBW, PaCO2 45-60 mm Hg
Number of subjects: 60
Study: 24731535

Group type: EXPERIMENTAL
Intervention: Multidisciplinary care plus laparoscopic adjustable gastric band surgery
Number of subjects: 51

Group type: COMPARATOR
Intervention: Multidisciplinary care only
Number of subjects: 51
Study: 22808053

Group type: EXPERIMENTAL
Intervention: Standard walking program (30 minutes/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High walking program (60 minutes/day)
Number of subjects: 16
Study: 19407724

Group type: EXPERIMENTAL
Intervention: Levetiracetam (mean endpoint dose: 2,044.1±1,065.2 mg/day, range: 250-3,000 mg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 17
Study: 17463215

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone and 4 mg glimepiride (coadministered)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone and 4 mg glimepiride (fixed-dose combination)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Fixed-dose combination vs coadministered
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Gender analysis
Number of subjects: 37
Study: 15094153

Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy elderly
Number of subjects: 0
Study: 11876711

Group type: EXPERIMENTAL
Intervention: Eradication therapy (omeprazole 20 mg b.d., clarithromycin 250 mg b.d., tinidazole 500 mg b.d. for 7 days)
Number of subjects: 2329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2329
Study: 9647172

Group type: EXPERIMENTAL
Intervention: Radical resection (> 90%)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Less extensive resection (<= 90%)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Radical resection (> 90%) for anaplastic astrocytoma
Number of subjects: 131

Group type: COMPARATOR
Intervention: Less extensive resection (<= 90%) for anaplastic astrocytoma
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Radical resection (> 90%) for glioblastoma multiforme
Number of subjects: 131

Group type: COMPARATOR
Intervention: Less extensive resection (<= 90%) for glioblastoma multiforme
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Improvement in preoperative neurological deficits
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Improvement in level of consciousness
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: New or increased neurological deficits
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Diminished sensorium after surgery
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Postoperative nonneurological complications (infection, hematoma, CSF fistula)
Number of subjects: 131
Study: 9031268

Group type: EXPERIMENTAL
Intervention: Physical training (30 min of bicycling daily or an equal amount of other physical activities)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Maintenance of the usual lifestyle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 30